ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.58
0.50%
US Tech 100
21,296.00
-0.05%
S&P 500
6,118.71
0.53%
US Dollar vs CAD
1.4316
-0.44%
Bitcoin
105,311.72
1.29%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Arcadis NV (ARCAD) Share Price

Arcadis NV

Arcadis NV (ARCAD)

EU
55.25
0.10
( 0.18% )
Updated: 03:20:10
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
55.25
Bid
55.20
Ask
55.30
Volume
5,446
55.15 Day's Range 55.40
47.72 52 Week Range 66.85
Market Cap
4.971B
Previous Close
55.15
Open
55.25
Last Trade
28
@
55.25
Last Trade Time
03:20:10
Financial Volume
-
VWAP
-
Average Volume (3m)
136,420
Shares Outstanding
89,973,000
Dividend Yield
-
PE Ratio
31.07
Earnings Per Share (EPS)
1.78
Revenue
5.01B
Net Profit
159.98M

About Arcadis NV

Sector
Engineering Services
Industry
Engineering Services Civil
Website
www.arcadis.com
Headquarters
Amsterdam, North Holland, Nld
Founded
1888
Arcadis NV is listed in the Engineering Services sector of the Euronext with ticker ARCAD. The last closing price for Arcadis NV was 55.15 €. Over the last year, Arcadis NV shares have traded in a share price range of 47.72 € to 66.85 €.

Arcadis NV currently has 89,973,000 shares outstanding. The market capitalization of Arcadis NV is 4.96 € billion. Arcadis NV has a price to earnings ratio (PE ratio) of 31.07.

Ask ADVFN Intelligence (AI)

ARCAD Latest News

More News

Arcadis completes share buyback program and reports final transactions

Arcadis completes share buyback program and reports final transactions Arcadis completes share buyback program and reports final transactions Amsterdam, December 9, 2024 – Arcadis (EURONEXT:...

December 09 2024
UK Regulatory

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program Amsterdam, December 2, 2024 – Arcadis (EURONEXT: ARCAD...

December 02 2024
UK Regulatory

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program Amsterdam, November 25, 2024 – Arcadis (EURONEXT: ARCAD...

November 25 2024
UK Regulatory

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program Amsterdam, November 18, 2024 – Arcadis (EURONEXT: ARCAD...

November 18 2024
UK Regulatory

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program   Arcadis reports transactions under its current share buyback program Amsterdam, November 11, 2024 – Arcadis (EURONEXT:...

November 11 2024
UK Regulatory

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program Amsterdam, November 4, 2024 – Arcadis (EURONEXT: ARCAD...

November 04 2024
UK Regulatory

Arcadis Trading Update Q3 2024: Multi-year wins drive significant order intake, margin expansion continues

Arcadis Trading Update Q3 2024: Multi-year wins drive significant order intake, margin expansion continues PRESS RELEASE Arcadis Third Quarter 2024 Trading UpdateMulti-year wins drive significant...

October 31 2024
UK Regulatory

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program   Arcadis reports transactions under its current share buyback program Amsterdam, October 28, 2024 – Arcadis (EURONEXT: ARCAD...

October 28 2024
UK Regulatory

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program Amsterdam, October 21, 2024 – Arcadis (EURONEXT: ARCAD...

October 21 2024
UK Regulatory

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Amsterdam, October 14, 2024 – Arcadis (EURONEXT: ARCAD), the leading data driven global Design & Consultancy organization...

October 14 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-1.7777777777856.2556.6555.1513899555.93873677DE
4-3.5-5.9574468085158.7559.453.3514141455.78825671DE
12-8.5-13.333333333363.7566.8553.3513642060.23469061DE
26-8.3-13.060582218763.5566.8553.3517930162.74064969DE
526.1512.525458248549.166.8547.7218468660.43253488DE
15617.7547.333333333337.566.8530.8414719647.79399678DE
26034.09161.10586011321.1666.8511.9115508138.94759655DE

ARCAD - Frequently Asked Questions (FAQ)

What is the current Arcadis NV share price?
The current share price of Arcadis NV is 55.25 €
How many Arcadis NV shares are in issue?
Arcadis NV has 89,973,000 shares in issue
What is the market cap of Arcadis NV?
The market capitalisation of Arcadis NV is EUR 4.96B
What is the 1 year trading range for Arcadis NV share price?
Arcadis NV has traded in the range of 47.72 € to 66.85 € during the past year
What is the PE ratio of Arcadis NV?
The price to earnings ratio of Arcadis NV is 31.07
What is the cash to sales ratio of Arcadis NV?
The cash to sales ratio of Arcadis NV is 0.99
What is the reporting currency for Arcadis NV?
Arcadis NV reports financial results in EUR
What is the latest annual turnover for Arcadis NV?
The latest annual turnover of Arcadis NV is EUR 5.01B
What is the latest annual profit for Arcadis NV?
The latest annual profit of Arcadis NV is EUR 159.98M
What is the registered address of Arcadis NV?
The registered address for Arcadis NV is GUSTAV MAHLERPLEIN 97, AMSTERDAM, NORTH HOLLAND, 1082 MS
What is the Arcadis NV website address?
The website address for Arcadis NV is www.arcadis.com
Which industry sector does Arcadis NV operate in?
Arcadis NV operates in the ENGINEERING SERVICES CIVIL sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AELISAelis Farma SA
2.70 €
(17.39%)
1.39k
ALTAILighton
21.30 €
(9.29%)
25.21k
KERKering
269.30 €
(8.94%)
278.78k
ALMASMastrad
0.022 €
(8.91%)
3M
ALMUNMunic S.A.
0.70 €
(8.02%)
21.68k
DMSBSDiagnostic Medical Systems
0.0045 €
(-35.71%)
80
ALMDTMedian Technologies
3.485 €
(-25.69%)
206.16k
ALARFAdeunis
0.748 €
(-18.70%)
900
ALBOOBOOSTHEAT
0.0568 €
(-17.68%)
15.59k
ALDOLDolfines
3.43 €
(-13.82%)
11.66k
ATOAtos SE
0.0022 €
(4.76%)
61.92M
ALCYBCybergun
0.0001 €
(0.00%)
24.54M
BCPBanco Comercial Portugues SA
0.5164 €
(-0.42%)
17.12M
ALVERVergnet
0.0014 €
(0.00%)
9.47M
BIOSBiosenic
0.0049 €
(-2.00%)
3.44M

Discussion

View Full Feed
tw0122 tw0122 8 minutes ago
.05 + 15% 3m traded
ACON
Seminole Red Seminole Red 10 minutes ago
Constitutional amendment to allow Trump third term introduced in the House

A Republican House member introduced a resolution to amend the U.S. Constitution to allow President Donald Trump — and any other future president — to be elected to serve a third term.
Rep. Andy Ogles of
Guido2 Guido2 11 minutes ago
Goa. I was born here.
FNMA
MagnetLover MagnetLover 14 minutes ago
No way. Or else he would be too busy Sam Altmanning himself.
FLCX
Peter J Peter J 16 minutes ago
It took .000774 to buy those 774 shares todays. Who does this?Very good Question, Badog. A VERY good question...

May I remind you that most of the times over the last years... it was exactly the other way around!

Now, who did/does this...? And why...?

ERHE
tw0122 tw0122 17 minutes ago
$7.51 still a little left for latecomers just cash it out now 
ALUR
10thMountain 10thMountain 21 minutes ago
Speaking of stair stepping…

https://stockcharts.com/c-sc/sc?s=FDCT&p=D&yr=1&mn=0&dy=0&i=t4669085127c&r=1737710215304
FDCT
RickNagra RickNagra 23 minutes ago
Which part of India are you in ?  I know the place very well.
FNMA
tw0122 tw0122 26 minutes ago
Flip back out .53 will revisit 
BTAI
Peter J Peter J 27 minutes ago
Ntephe and insiders are getting away with violating SEC filing and disclosure requirements, with refusing to hold annual shareholder meetings, and with paying themselves undisclosed amounts from undisclosed sources of revenue.

All very true, sounds like a stock I would like to follow
ERHE
RickNagra RickNagra 30 minutes ago
Oh wow.
DBMM
tw0122 tw0122 33 minutes ago
BTAI .49 on the move in some 
BTAI
Peter J Peter J 35 minutes ago
Couldn't use these shares as collateral to buy a rotisserie chicken at Costco.
Well... that firmly explains his obsession with ERHE... 🤣

The altruist gang has combined between 10 and 20 K ERHC posts...

Strategy, remember... all for the good cause! Don't
ERHE
joeycav11 joeycav11 41 minutes ago
Were so undervalued…
With this revenue a medium biotech company can buy us and multiply there balance sheet by 6 times easy.
Obviously company is not selling cheap
Shake up is coming in pharma dont miss it
Cell therapy is the panacea and proven cures like we possess is t
AMRN
Here Today Here Today 42 minutes ago
Another train of thought is that possibly those patients in the Cohorts 1 & 2 might have been talking to their family and friends about this new drug they are on and the results they are seeing so far causing those family and friends to start researching and looking into the company and drug and the
RNAZ
Ribo Ribo 43 minutes ago
$BDPT, Dominate the Mat with Xcellara!!!

https://x.com/BioadaptivesInc/status/1882612437301834189
BDPT
Ribo Ribo 43 minutes ago
$BDPT, The Science Behind Xcellera!!!

https://x.com/BioadaptivesInc/status/1882610070749581750
BDPT
eagle8 eagle8 44 minutes ago
Peter Davis
@peter_brit
·
2h
#dcvax $nwbo #gbm

GPT-4o (Poe) Analysis providing additional context to the Information Disclosure Statement added by $nwbo to their combination patent.

The patent applicant for 18/489,222 (related to "Combinatio
NWBO
Seminole Red Seminole Red 44 minutes ago
yay
Seminole Red Seminole Red 52 minutes ago
Unusually windy conditions dominated Thursday’s second round at Torrey Pines. Gusts of 30 mph wreaked havoc on the field, with the only reprieve being the 90 minutes that play was delayed due to extreme conditions. Only 11 players had shot under-par rounds when play was suspended due to darkness. Bo
SteveSchiets SteveSchiets 58 minutes ago
Still you guys are here? Is that Future fault?

I'm here for the upswing, if that ever happens.
SEV
walterc walterc 58 minutes ago
well done
thank you
GCUMF

Your Recent History

EU
ARCAD
Arcadis NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads